ClinicalTrials.gg
RecruitingNCT07570147Updated May 28, 2026

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

A Phase 1 interventional study of ABBV-1451 and ABBV-1451 in Healthy Volunteer, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-1451
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .
  • Applies to Part 2 only:
  • For Japanese participants:

    -- Participant must be first or second-generation Japanese of full Japanese parentage, residing outside of Japan. First generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent. Participants must be in general good health.

  • For Han Chinese participants:

    • Participant must be first or second-generation Han Chinese of full Chinese parentage, residing outside of China. First generation participants will have been born in China to two parents and four grandparents also born in China of full Chinese descent. Second-generation participants born outside of China must have two parents and four grandparents born in China of full Chinese descent. Participants must be in general good health.

Exclusion criteria

Exclusion Criteria:

  • History: of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Part 1: Group 1

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 1: Group 2

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 1: Group 3

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 1: Group 4

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 1: Group 5

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 1: Group 6

    Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 2: Group 7

    Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo.

    Drug: ABBV-1451 · Other: Placebo

  • Experimental
    Part 2: Group 8

    Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo.

    Drug: ABBV-1451 · Other: Placebo

Interventions

  • DrugABBV-1451

    Injection

  • DrugABBV-1451

    Infusion

  • OtherPlacebo

    Injection

  • OtherPlacebo

    Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to Approximately Day 211

  2. Maximum Observed Plasma Concentration (Cmax) of ABBV-1451

    Cmax of ABBV-1451.

    Time frame: Up to Approximately Day 211

  3. Time to Cmax (Tmax) of ABBV-1451

    Tmax of ABBV-1451.

    Time frame: Up to Approximately Day 211

  4. Terminal Phase Elimination Rate Constant (β) of ABBV-1451

    β of ABBV-1451.

    Time frame: Up to Approximately Day 211

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451

    t1/2 of ABBV-1451.

    Time frame: Up to Approximately Day 211

  6. Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451

    AUCt of ABBV-1451.

    Time frame: Up to Approximately Day 211

  7. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451

    AUCinf of ABBV-1451.

    Time frame: Up to Approximately Day 211

07

Study locations

1 of 1 sites recruiting
  • Acpru /Id# 282128
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartActual
May 1, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570147
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 6, 2026
Start date
May 1, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 28, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion